amyotrophic lateral sclerosis
FDA decision on Neurizon’s ALS therapy delayed until October
August 18, 2025Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis
Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
August 7, 2025Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
Neurizon confirms positive results for prospective ALS treatment
June 23, 2025Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
June 9, 2025Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
Broken String Biosciences and the Francis Crick Institute collaborate on ALS research
May 7, 2024Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics
Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …
FDA knocks back Biohaven’s ALS drug over manufacturing concerns
July 22, 2019Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma
Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …
Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS
May 7, 2019Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma
Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …
Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies
June 21, 2018Research and Development, Sales and Marketing Aquinnah Pharmaceuticals, als, amyotrophic lateral sclerosis, pharma
Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders …
Biogen Idec buys neurodegenerative disease rights
December 21, 2010Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
